Biogen

Youtube Subscribe

Open: 237.65 Close: 239.29 Change: 1.64

Are you looking for information about Biogen Company Inc Stock? We programmed an AI to summarize it for you.

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, stock, price, analyst, Cowen, target, year, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Cowen believes Biogen ( NASDAQ: BIIB ) is set to perform well next year and has named the stock one of its top picks for 2024. Cowen admits that the last few years have seen declining revenues for Biogen.

Today's News

Biogen (biib) stock forecast, price targets and analysts predictions - tipranks.com.com. Biogen has 30.35% upside potential, based on the analysts average price target of $311.92. Cowen believes that Biogen ( NASDAQ: BIIB ) is set to perform well next year and has named the stock one of its top picks for 2024. Cowen admits that the last few years have seen declining revenues for Biogen. The company is expected to save approximately $1 billion by 2025. Ipsen terminating one of its programs, Ipsen let go 21 members of its lab staff. Sangamo Therapeutics is now laying off around 120 employees—27% of its U.S. workforce. Biogen has several drug candidates in phase 3 trials in neurology-related fields. Biogen upgraded, Take-Two downgraded: Wall Streets top analyst calls Biogen upgrades, Take Two downgrades. New BPCIA Case Filed: Genentech and Biogen Want to Stop Dr. reddys rituximab biosimilar from entering the u.s. market. Biogen named a best idea for 2024 at Cowen. Biogen Inc.s (NASDAQ:BIIB) recent price movement underpinned by its weak Fundamentals? It is hard to get excited after looking at Biogens recent performance, when its stock has declined 7.7% over the past three months. Biogen offers therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. Biogen also manufactures and commercializes biosimilars.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, stock, price, analyst, Cowen, target, year, and the most common words in the summary are: biogen, stock, job, analyst, market, news, top, . One of the sentences in the summary was: Cowen admits that the last few years have seen declining revenues for Biogen.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #job #analyst #market #news #top.

Read more →

Youtube Subscribe

---